

**Company**

**SANSHO Co., Ltd.**



**Presenter**

**Toshiro Morohoshi, Ph.D.**



We SANSHO are developing a new drug, 2ccPA (2-carba cyclic phosphatidic acid) for osteoarthritis and are now conducting clinical trial of phase 1/b.

This product is a low molecule and the mechanism of this one is to inhibits ATX(Autotaxin enzyme).



**1. Promotion of Hyaluronan Production**

- human articular chondrocytes, human synoviocytes chondrocytes and synoviocytes derived from OA patients

**2. Suppression of Enzymes That Induce Cartilage Degradation**

- matrix metalloproteinases (MMP-1, -3, and -13)
- aggrecanases (ADAMTS-4 and -5)

**3. Anti-Inflammatory Action**

- reduction in swelling in a rabbit OA model

**4. Analgesic Action**

- reduction in PGE2 in a rabbit OA model
- suppression of neuropathic pain

ATX/LPA axis:

Obtained data suggest that 2ccPA endogenously inhibits LPA production by way of affecting ATX.